Company news

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) news

Edgewise Therapeutics, Inc. news releases on 6ix. Latest, Oct 1, 2026: Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) news

Press releases & updates

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

Edgewise Therapeutics : Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)